版权说明 操作指南
首页 > 成果 > 详情

Lipoprotein lipase activator NO-1886

认领
导出
下载 Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Yin, WD*;Tsutsumi, K
通讯作者:
Yin, WD
作者机构:
[Yin, WD] Nanhua Univ, Sch Med, Dept Biochem & Mol Biol, Hengyang 421001, Peoples R China.
Otsuka Pharmaceut Factory Inc, Res & Dev, Tokushima, Japan.
通讯机构:
[Yin, WD] N
Nanhua Univ, Sch Med, Dept Biochem & Mol Biol, Hengyang 421001, Peoples R China.
语种:
英文
关键词:
Atherosclerosis;Cardiovascular disease;Lipids;Lipoprotein lipase
期刊:
Cardiovascular Therapeutics
ISSN:
1755-5914
年:
2003
卷:
21
期:
2
页码:
133-142
机构署名:
本校为第一且通讯机构
院系归属:
化学化工学院
医学院
药学与生物科学学院
摘要:
Lipoprotein lipase (LPL) is a rate-limiting enzyme that hydrolyzes circulating triglyceride-rich lipoproteins such as very low-density lipoproteins and chylomicrons. A decrease in LPL activity is associated with an increase in plasma triglycerides (TG) and a decrease in plasma high-density lipoprotein cholesterol (HDL-C). The increase in plasma TG and decrease in plasma HDL-C are risk factors for cardiovascular disease. Tsutsumi et al. hypothesized that elevating LPL activity would cause a reduction of plasma TG and an increase in plasma HDL-C, resulting in protection against the development o...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com